Abstract
Background: As the human lifespan increases, the number of people affected by agerelated dementia is growing at an epidemic pace. Vascular pathology dramatically affects cognitive profiles, resulting in dementia and cognitive impairment. While vascular dementia itself constitutes a medical challenge, hypo-perfusion/vascular risk factors enhance amyloid toxicity and other memory- damaging factors and hasten Alzheimer’s disease (AD) and other memory disorders’ progression, as well as negatively affect treatment outcome.
Methods: Research and online content related to vascular cognitive impairment and dementia is reviewed, specifically focusing on the potential treatment of the disorder.
Results: Few therapeutic options are currently available to improve the prognosis of patients with vascular dementia and cognitive impairment, mixed AD dementia with vascular pathology, or other memory disorders. Emerging evidence, however, indicates that, like AD and other memory disorders, synaptic impairment underlies much of the memory impairment in the cognitive decline of vascular cognitive impairment and vascular dementia.
Conclusion: Effective rescues of the memory functions might be achieved through synaptic and memory therapeutics, targeting distinct molecular signaling pathways that support the formation of new synapses and maintaining their connections. Potential therapeutic agents include: 1) memory therapeutic agents that rescue synaptic and memory functions after the brain insults; 2) antipathologic therapeutics and an effective management of vascular risk factors; and 3) preventative therapeutic agents that achieve memory therapy through functional enhancement. These therapeutic agents are also likely to benefit patients with AD and/or other types of memory disorders.
Keywords: Vascular dementia, vascular cognitive impairment, mixed dementia, Alzheimer’s disease, memory therapeutics, synaptogenesis, cerebral reserve, vascular risk factors, diabetes, hypertension, small vessel disease, stem cells, synaptic therapeutics.
Current Neuropharmacology
Title:Potential Therapeutics for Vascular Cognitive Impairment and Dementia
Volume: 16 Issue: 7
Author(s): Miao-Kun Sun*
Affiliation:
- Blanchette Rockefeller Neurosciences Institute, 8 Medical Center Drive, Morgantown, West Virginia 26505,United States
Keywords: Vascular dementia, vascular cognitive impairment, mixed dementia, Alzheimer’s disease, memory therapeutics, synaptogenesis, cerebral reserve, vascular risk factors, diabetes, hypertension, small vessel disease, stem cells, synaptic therapeutics.
Abstract: Background: As the human lifespan increases, the number of people affected by agerelated dementia is growing at an epidemic pace. Vascular pathology dramatically affects cognitive profiles, resulting in dementia and cognitive impairment. While vascular dementia itself constitutes a medical challenge, hypo-perfusion/vascular risk factors enhance amyloid toxicity and other memory- damaging factors and hasten Alzheimer’s disease (AD) and other memory disorders’ progression, as well as negatively affect treatment outcome.
Methods: Research and online content related to vascular cognitive impairment and dementia is reviewed, specifically focusing on the potential treatment of the disorder.
Results: Few therapeutic options are currently available to improve the prognosis of patients with vascular dementia and cognitive impairment, mixed AD dementia with vascular pathology, or other memory disorders. Emerging evidence, however, indicates that, like AD and other memory disorders, synaptic impairment underlies much of the memory impairment in the cognitive decline of vascular cognitive impairment and vascular dementia.
Conclusion: Effective rescues of the memory functions might be achieved through synaptic and memory therapeutics, targeting distinct molecular signaling pathways that support the formation of new synapses and maintaining their connections. Potential therapeutic agents include: 1) memory therapeutic agents that rescue synaptic and memory functions after the brain insults; 2) antipathologic therapeutics and an effective management of vascular risk factors; and 3) preventative therapeutic agents that achieve memory therapy through functional enhancement. These therapeutic agents are also likely to benefit patients with AD and/or other types of memory disorders.
Export Options
About this article
Cite this article as:
Sun Miao-Kun *, Potential Therapeutics for Vascular Cognitive Impairment and Dementia, Current Neuropharmacology 2018; 16 (7) . https://dx.doi.org/10.2174/1570159X15666171016164734
| DOI https://dx.doi.org/10.2174/1570159X15666171016164734 |
Print ISSN 1570-159X |
| Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
Call for Papers in Thematic Issues
Advances and Integrative Approaches to Gut-Brain Interactions
Disorders of gut-brain interaction (DGBIs), formerly known as functional gastrointestinal disorders, involve dysfunction of complex signaling pathways between the gastrointestinal tract and the central nervous system. These disorders span the esophagus (functional heartburn, functional dysphagia), stomach (functional dyspepsia), and intestines (irritable bowel syndrome, chronic constipation), and are increasingly recognized as ...read more
Advances in Neuroimaging: Bridging Pharmacology, Nanotechnology, and Neurological Disorders
This special topic seeks to compile cutting-edge research and reviews that explore the synergy between neuroimaging, pharmacology, and nanotechnology in understanding and treating neurological disorders. We aim to elucidate novel imaging biomarkers for tracking drug efficacy and disease progression in conditions such as Alzheimer’s, Parkinson’s, multiple sclerosis, and brain tumors. ...read more
Advances in Neuroinflammation and Neuroprotection: Mechanisms and Therapeutic Frontiers
It offers a comprehensive exploration of neuroinflammatory and neuroprotective pathways that play central roles in a range of neurological disorders, including stroke, traumatic brain injury, and neurodegenerative diseases such as Alzheimer’s and Parkinson’s. This issue invites research on the cellular and molecular mechanisms driving neuroinflammation, such as the roles of ...read more
Advances in Neurovascular Unit in Stroke and Neurodegenerative Disease: Mechanisms and Therapeutic Frontiers
The main goal of this special issue is to analyze current knowledge of the functional roles of various types of cells in neurovascular units(NVU) in neurodegenerative diseases such as stroke, Alzheimer's disease, and Parkinson's disease. This issue invites research on the cellular and molecular mechanisms driving inflammation, blood-brain barrier(BBB) injury, ...read more
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anticoagulant Therapy in Very Old Patients
Cardiovascular & Hematological Disorders-Drug Targets Assembly, Maturation, and Trafficking of the γ-Secretase Complex in Alzheimers Disease
Current Alzheimer Research Prospective Role of MicroRNAs in Depression
Current Medicinal Chemistry Potential Targets for the Development of Novel Antidepressants: Future Perspectives
CNS & Neurological Disorders - Drug Targets Right Temporal Variant Frontotemporal Dementia Misdiagnosed as Schizophrenia
Current Psychiatry Research and Reviews Combining in vitro and in silico Approaches to Find New Candidate Drugs Targeting the Pathological Proteins Related to the Alzheimer's Disease
Current Neuropharmacology Nanoparticle Delivery of Transition-Metal Chelators to the Brain: Oxidative Stress will Never See it Coming!
CNS & Neurological Disorders - Drug Targets Alzheimer’s Disease and Environmental Exposure to Lead: The Epidemiologic Evidence and Potential Role of Epigenetics
Current Alzheimer Research NGA- A Novel Hypothetical Drug Model: Combinatorial Approach to Multifactorial Alzheimer's Disease
Current Drug Discovery Technologies Central Selective Acetylcholinesterase Inhibitor with Neurotrophic Activity Structure-Activity Relationships of TAK-147 and Related Compounds
Current Medicinal Chemistry Critical Review of Malondialdehyde Analysis in Biological Samples
Current Pharmaceutical Analysis Distinctive Effects of Aerobic and Resistance Exercise Modes on Neurocognitive and Biochemical Changes in Individuals with Mild Cognitive Impairment
Current Alzheimer Research Anti-Amyloidogenic and Anti-Apoptotic Role of Melatonin in Alzheimer Disease
Current Neuropharmacology Preface:
CNS & Neurological Disorders - Drug Targets A Review: Natural Compounds as Anti-Alzheimer´s Disease Agents
Current Nutrition & Food Science State Dissociation, Human Behavior, and Consciousness
Current Topics in Medicinal Chemistry Genetic Susceptibility to Behavioural and Psychological Symptoms in Alzheimer Disease
Current Alzheimer Research Allocentric to Egocentric Spatial Switching: Impairment in aMCI and Alzheimer's Disease Patients?
Current Alzheimer Research Doing the Puzzle of Steroid Hormone Action: Biological Functions, Physiological and Clinical Significance of Plasma Membrane-Residing Glucocorticoid Recognizing Proteins
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Histological and Direct Evidence for the Role of Complement in the Neuroinflammation of AD
Current Alzheimer Research





